RxDoctor Payments Data

John Chukwudifu, PA

Physician Assistant · Lemoyne, PANPI 1033628235

Payments from drug & device makers

$4,640in general payments, 2019–2025

Across 239 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Bristol Myers Squibb$1K
  • Lundbeck LLC$554
  • EMD Serono, Inc.$387
  • Teva Pharmaceuticals USA, Inc.$322
  • Biohaven Pharmaceutical Holding Company Ltd.$182
  • plus $781 from 16 others

What the payments were for

  • Food & beverage$4,55298%
  • Education$872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,640 in reported general payments places this provider in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$14,002
Medicare patients
121
Services billed
159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant30$42,117
Nurtec OdtRimegepant Sulfate29$30,244
QuliptaAtogepant16$22,898
Emgality PenGalcanezumab-Gnlm21$14,292
Aimovig AutoinjectorErenumab-Aooe19$14,223
Oxtellar XrOxcarbazepine11$9,863
Lamotrigine ErLamotrigine26$7,252
Levetiracetam126$4,874
Lacosamide30$4,825
Carbidopa-LevodopaCarbidopa/Levodopa53$2,680
Memantine Hcl142$2,633
Donepezil Hcl200$2,549
Levetiracetam ErLevetiracetam12$2,261
Topiramate83$1,132
Lamotrigine37$859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,341$65,01546 claims
PfizerNurtec Odt$80$30,24429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Lemoyne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →